PubRank

Detlef Schuppan

Author PubWeight™ 175.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004 6.14
2 Herbal hepatotoxicity. J Hepatol 2005 3.98
3 IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010 3.57
4 Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008 2.89
5 Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med 2012 2.58
6 Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009 2.16
7 Update on serologic testing in celiac disease. Am J Gastroenterol 2010 2.07
8 The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 2011 1.96
9 Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011 1.85
10 Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007 1.82
11 The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009 1.77
12 Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013 1.74
13 Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 2013 1.73
14 Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008 1.69
15 Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol 2003 1.64
16 Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005 1.62
17 Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology 2011 1.61
18 Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology 2013 1.59
19 [Prevalence of circulating autoantibodies in healthy individuals]. Med Klin (Munich) 2002 1.52
20 Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998. Eur J Epidemiol 2006 1.51
21 Pathomechanisms in celiac disease. Int Arch Allergy Immunol 2003 1.51
22 Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol 2011 1.48
23 Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008 1.47
24 Endoscopic ultrasound-guided endoscopic necrosectomy of the pancreas: is irrigation necessary? Surg Endosc 2011 1.46
25 Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003 1.45
26 EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 2006 1.45
27 Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol 2010 1.40
28 Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 2006 1.40
29 Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009 1.39
30 Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 2006 1.38
31 Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2012 1.37
32 Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002 1.36
33 EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005 1.35
34 Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol 2010 1.33
35 Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003 1.33
36 Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008 1.31
37 World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol 2013 1.29
38 Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004 1.28
39 Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion 2004 1.26
40 The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002 1.25
41 A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol 2009 1.24
42 HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem 2010 1.24
43 Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005 1.24
44 Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006 1.21
45 Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology 2010 1.20
46 Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol 2005 1.18
47 Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2012 1.18
48 Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010 1.17
49 Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 2006 1.14
50 Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 2003 1.14
51 Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005 1.13
52 Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci 2008 1.12
53 Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology 2005 1.12
54 Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 2004 1.12
55 Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 2012 1.10
56 The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006 1.09
57 Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med 2005 1.07
58 Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012 1.06
59 Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006 1.04
60 Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007 1.04
61 Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007 1.03
62 Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol 2006 1.03
63 Discovery of a novel and rich source of gluten-degrading microbial enzymes in the oral cavity. PLoS One 2010 1.00
64 Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011 1.00
65 Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology 2007 1.00
66 Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 2006 0.99
67 A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol 2009 0.99
68 Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 2005 0.97
69 Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005 0.97
70 Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol 2003 0.96
71 Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006 0.96
72 Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract. PLoS One 2011 0.96
73 Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One 2010 0.96
74 Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential. FASEB J 2005 0.94
75 Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol 2013 0.94
76 Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense decrements of oxygen but not hypoxia per se. Free Radic Biol Med 2008 0.93
77 Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003 0.93
78 Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006 0.92
79 In vitro differentiation of human monocytes into dendritic cells by peptic-tryptic digest of gliadin is independent of genetic predisposition and the presence of celiac disease. J Clin Immunol 2008 0.91
80 Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J Immunol 2004 0.91
81 The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 2005 0.90
82 Epithelial-to-mesenchymal transition in liver fibrosis: dead or alive? Gastroenterology 2010 0.90
83 VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2005 0.90
84 Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res 2003 0.90
85 Human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis. Gastroenterology 2010 0.89
86 Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol 2004 0.89
87 Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol 2011 0.89
88 Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 2004 0.89
89 Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M. J Biol Chem 2001 0.88
90 Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol 2009 0.88
91 Liver-homing of purified glucose oxidase: a novel in vivo model of physiological hepatic oxidative stress (H2O2). J Hepatol 2006 0.88
92 Nondietary therapies for celiac disease. Gastrointest Endosc Clin N Am 2012 0.87
93 Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005 0.87
94 Monitoring nonresponsive patients who have celiac disease. Gastrointest Endosc Clin N Am 2006 0.87
95 Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 2002 0.87
96 Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med 2004 0.86
97 The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease. Autoimmun Rev 2004 0.86
98 Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood 2002 0.86
99 Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 2005 0.86
100 Microparticles: Modulators and biomarkers of liver disease. J Hepatol 2012 0.86
101 Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy. Acta Neuropathol 2004 0.85
102 Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 2012 0.85
103 Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol 2008 0.85
104 AMPK regulates macrophage polarization in adipose tissue inflammation and NASH. J Hepatol 2012 0.84
105 The epithelial mitogen keratinocyte growth factor binds to collagens via the consensus sequence glycine-proline-hydroxyproline. J Biol Chem 2002 0.84
106 Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 2006 0.84
107 Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. World J Gastroenterol 2013 0.84
108 Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. Biochem Biophys Res Commun 2005 0.83
109 Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology 2015 0.82
110 Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006 0.82
111 Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J Hepatol 2010 0.82
112 Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology 2006 0.82
113 Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci 2002 0.82
114 Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 2005 0.82
115 TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005 0.81
116 Dendritic cells in liver injury and fibrosis: shortcomings and promises. J Hepatol 2013 0.81
117 Helicobacter pylori upregulates prion protein expression in gastric mucosa: a possible link to prion disease. World J Gastroenterol 2005 0.81
118 A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. Oncol Rep 2004 0.81
119 The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro. Int J Cancer 2003 0.81
120 The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes. J Biol Chem 2005 0.81
121 Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol 2012 0.80
122 Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Hepatology 2012 0.80
123 The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma. J Hepatol 2004 0.80
124 Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003 0.80
125 Increased plasma levels of microparticles expressing CD39 and CD133 in acute liver injury. Transplantation 2013 0.80
126 CD8+ T cells drive adipose tissue inflammation--a novel clue for NASH pathogenesis? J Hepatol 2009 0.80
127 Integrin-mediated control of cell growth. Hepatology 2003 0.80
128 Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005 0.79
129 Hepatocyte growth factor and c-Met expression in rat and human liver fibrosis. Liver Int 2004 0.79
130 Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential. ChemMedChem 2014 0.79
131 No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res 2008 0.79
132 Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J Hepatol 2005 0.78
133 Synthesis of collagen I in collagenous sprue. Clin Gastroenterol Hepatol 2006 0.78
134 Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int 2014 0.78
135 Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. J Hepatol 2011 0.78
136 Food, the immune system, and the gastrointestinal tract. Gastroenterology 2015 0.78
137 Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003 0.78
138 Testing safety of germinated rye sourdough in a celiac disease model based on the adoptive transfer of prolamin-primed memory T cells into lymphopenic mice. Am J Physiol Gastrointest Liver Physiol 2014 0.78
139 When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. Am J Physiol Gastrointest Liver Physiol 2012 0.78
140 Endothelin-1 enhances fibrogenic gene expression, but does not promote DNA synthesis or apoptosis in hepatic stellate cells. Comp Hepatol 2006 0.78
141 Spatial and temporal pattern of expression of interstitial collagenase, stromelysin/transin, gelatinase A, and TIMP-1 during experimental gastric ulcer healing. Digestion 2004 0.77
142 Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol 2008 0.77
143 CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012 0.77
144 Potentiated anticancer effects on hepatoma cells by the retinoid adapalene. Cancer Lett 2004 0.77
145 Open conformation tissue transglutaminase testing for celiac dietary assessment. Dig Liver Dis 2012 0.77
146 Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017 0.77
147 A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis. Liver Int 2010 0.77
148 Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med 2007 0.77
149 Portal vein arterialisation as a technical option in liver transplantation: impact on function, regeneration, and morphology of the liver following hemihepatectomy in pigs. Liver Int 2003 0.77
150 Celiac disease and endocrine autoimmunity. Dig Dis 2015 0.76
151 In vitro and in vivo models of celiac disease. Expert Opin Drug Discov 2009 0.76
152 Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis. Liver 2002 0.76
153 Serum fibrosis markers to predict clinical and histological progression in hepatitis C non-responders. Gut 2010 0.75
154 Refractory coeliac disease: one step closer to the origin of aberrant lymphocytes. Gut 2012 0.75
155 In reply. Dtsch Arztebl Int 2014 0.75
156 Turning swords into plowshares: transglutaminase to detoxify gluten. Gastroenterology 2007 0.75
157 Elevated transaminases as a predictor of coma in a patient with anorexia nervosa: a case report and review of the literature. J Med Case Rep 2010 0.75
158 Hepatocellular carcinomas do not compromise quantitative tests of liver function. Hepatogastroenterology 2005 0.75
159 Central role of IL-6 and MMP-1 for cross talk between human intestinal mast cells and human intestinal fibroblasts. Immunobiology 2012 0.75
160 Autoimmunity and HCV infection in porphyria cutanea tarda: a controlled study. Cell Mol Biol (Noisy-le-grand) 2002 0.75
161 Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. Eur J Gastroenterol Hepatol 2016 0.75
162 Changes in hepatic perfusion after administration of hydroxyethyl starch in intensive care patients assessed using color-coded Doppler sonography. Clin Imaging 2002 0.75
163 Small bowel: from sideline to center stage in gastroenterology. Dig Dis 2015 0.75
164 Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C. Clin Transplant 2011 0.75